Spots Global Cancer Trial Database for tpi 287
Every month we try and update this database with for tpi 287 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases | NCT02187822 | Brain Metastase... Generalized Mal... Brain Lesions | TPI 287 Fractionated St... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer | NCT00553813 | Pancreatic Canc... | TPI 287 | 18 Years - | Cortice Biosciences, Inc. | |
| Open-Label Study of TPI 287 for Patients With Metastatic Melanoma | NCT01340729 | Metastatic Mela... | TPI 287 | 15 Years - | M.D. Anderson Cancer Center | |
| A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma | NCT01067066 | Melanoma | TPI 287 Temodar (Temozo... | 15 Years - | M.D. Anderson Cancer Center | |
| Open-Label Study of TPI 287 for Patients With Metastatic Melanoma | NCT01340729 | Metastatic Mela... | TPI 287 | 15 Years - | M.D. Anderson Cancer Center | |
| TPI 287 in Breast Cancer Metastatic to the Brain | NCT01332630 | Breast Cancer | TPI 287 Dexamethasone Benadryl Ranitidine | 18 Years - | M.D. Anderson Cancer Center | |
| TPI 287 in Patients With Recurrent Glioblastoma Multiforme | NCT01113463 | Brain Cancer | TPI 287 | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer | NCT00479635 | Prostate Cancer | TPI 287 TPI 287 | 18 Years - | Cortice Biosciences, Inc. | |
| Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases | NCT02187822 | Brain Metastase... Generalized Mal... Brain Lesions | TPI 287 Fractionated St... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer | NCT00553813 | Pancreatic Canc... | TPI 287 | 18 Years - | Cortice Biosciences, Inc. | |
| Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma | NCT01505608 | Neuroblastoma | TPI 287 Temozolomide Irinotecan | 12 Months - 21 Years | Milton S. Hershey Medical Center | |
| TPI 287 in Breast Cancer Metastatic to the Brain | NCT01332630 | Breast Cancer | TPI 287 Dexamethasone Benadryl Ranitidine | 18 Years - | M.D. Anderson Cancer Center | |
| Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma | NCT01933815 | Glioblastoma Mu... | TPI 287 Bevacizumab | 18 Years - | Cortice Biosciences, Inc. | |
| A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer | NCT00479635 | Prostate Cancer | TPI 287 TPI 287 | 18 Years - | Cortice Biosciences, Inc. | |
| TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma | NCT00867568 | Neuroblastoma Medulloblastoma Relapse | TPI 287 | 12 Months - 21 Years | Milton S. Hershey Medical Center | |
| A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma | NCT01067066 | Melanoma | TPI 287 Temodar (Temozo... | 15 Years - | M.D. Anderson Cancer Center | |
| Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma | NCT01483820 | Neuroblastoma Medulloblastoma | TPI 287 | 12 Months - 30 Years | Milton S. Hershey Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
